A recent study from the Ludwig Institute for Cancer Research Limited, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7DQ, United Kingdom shows that “iASPP, a previously unidentified regulator of desmosomes, prevents arrhythmogenic right ventricular cardiomyopathy ….” This study was published in the 17 February 2015 issue of Proc Natl Acad Sci U S A by Prof Xin Lu, Dr. Notari M, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based molecular therapy for Right ventricular cardiomyopathy: Deubiquitylase HAUSP suppresses arrhythmogenic right ventricular cardiomyopathy via down regulation of its target gene. Thus, pharmacological formulations encompassing “HAUSP activators” may be used to inhibit arrhythmogenic right ventricular cardiomyopathy.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based molecular therapy for Right ventricular cardiomyopathy: Deubiquitylase HAUSP suppresses arrhythmogenic right ventricular cardiomyopathy via down regulation of its target gene, 24/February/2015, 19.12, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Amount: $ 500*
Undisclosed information: How HAUSP suppresses arrhythmogenic right ventricular cardiomyopathy